A Phase II Trial of Thalidomide (NSC 66847, IND 48832) for Patients With Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2012
At a glance
- Drugs Thalidomide (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2009 Status changed from completed to recruiting as reported by ClinicalTrials.gov.